Allergy Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Allergy Therapeutics has a total shareholder equity of £26.5M and total debt of £1.6M, which brings its debt-to-equity ratio to 6%. Its total assets and total liabilities are £69.1M and £42.6M respectively.
Key information
6.0%
Debt to equity ratio
UK£1.58m
Debt
Interest coverage ratio | n/a |
Cash | UK£13.52m |
Equity | UK£26.46m |
Total liabilities | UK£42.62m |
Total assets | UK£69.08m |
Recent financial health updates
Financial Position Analysis
Short Term Liabilities: AGY's short term assets (£35.3M) exceed its short term liabilities (£25.3M).
Long Term Liabilities: AGY's short term assets (£35.3M) exceed its long term liabilities (£17.3M).
Debt to Equity History and Analysis
Debt Level: AGY has more cash than its total debt.
Reducing Debt: AGY's debt to equity ratio has reduced from 6.2% to 6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGY has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: AGY has less than a year of cash runway if free cash flow continues to reduce at historical rates of 47.6% each year